Term
|
Definition
| GABA enhancer, intermediate time to sedation if given IV |
|
|
Term
|
Definition
| GABA enhancer, extremely fast time to sedation if given IV |
|
|
Term
|
Definition
| GABA enhancer, slow acting, but long lasting, sedation if given IV |
|
|
Term
|
Definition
| Acetylcholinesterase inhibitor, can enter the brain, but it is not used for brain disorders |
|
|
Term
|
Definition
| Acetylcholinesterase inhibitor, can't enter the brain |
|
|
Term
|
Definition
| Muscarinic and nicotinic receptor agonist |
|
|
Term
|
Definition
| Acetylcholinesterase inhibitor, short duration of action, reverses muscle paralysis in anesthesia |
|
|
Term
|
Definition
| Irreversible acetylcholinesterase inhibitor, can be used for glaucoma |
|
|
Term
|
Definition
| Irreversible acetylcholinesterase inhibitor, no medical use |
|
|
Term
|
Definition
| Muscarinic agonist, for GI motility |
|
|
Term
|
Definition
| Muscarinic agonist, glaucoma treatment |
|
|
Term
|
Definition
| Muscarinic agonist, from mushrooms |
|
|
Term
|
Definition
| Increases heart rate and blood pressure, nicotinic agonist |
|
|
Term
|
Definition
| Muscarinic antagonist, increases heart rate, causes dry mouth |
|
|
Term
|
Definition
| Nicotinic antagonist at the neuromuscular junction |
|
|
Term
|
Definition
| Nicotinic antagonist at the ganglia |
|
|
Term
|
Definition
| Nucleophile to break sarin bond to acetylcholinesterase |
|
|
Term
|
Definition
| Acetylcholinesterase inhibitor, site of action is the brain |
|
|
Term
|
Definition
| Alpha 1, Alpha 2, Beta 1, Beta 2 agonist |
|
|
Term
|
Definition
| Alpha 1, Alpha 2, Beta 1 agonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Alpha 1 agonist, leading to increase in blood pressure and reflexive decrease in heart rate |
|
|
Term
|
Definition
| Competitive alpha 1 and alpha 2 antagonist |
|
|
Term
|
Definition
| Tyrosine hydroxylase inhibitor, blocks all catecholamine synthesis in CNS and periphery |
|
|
Term
|
Definition
| Increases dopamine production, used to treat Parkinson's Disease |
|
|
Term
|
Definition
| Alpha 2 agonist used to decrease blood pressure in an oral formulation |
|
|
Term
|
Definition
| Increaes the release of norepinephrine, but is normally metabolized quickly by MAO. Only significant if MAO is inhibited |
|
|
Term
|
Definition
| Catecholamine reuptake inhibitor, increases norepinephrine release by reversing the reuptake pump |
|
|
Term
|
Definition
| Increases release of norepinephrine, weak agonist of alpha 1, beta 1, beta 2. Used as a decongestant |
|
|
Term
|
Definition
| Catecholamine reuptake inhibitor, local anesthetic properties |
|
|
Term
|
Definition
| Selectively inhibits norepinephrine reuptake |
|
|
Term
|
Definition
| Non-selective MAO inhibitor |
|
|
Term
|
Definition
| Selective MAO-B inhibitor |
|
|
Term
|
Definition
| Phosphodiesterase inhibitor that can increase cardiac stimulation leading to arrhythmias, and can increase CNS excitation leading to convulsions. Used to treat apnea in infants. |
|
|
Term
|
Definition
| Phosphodiesterase inhibitor that increases cyclic GMP to relax vascular smooth muscle |
|
|
Term
|
Definition
| Low dose dilates renal vasculature, higher dose causes cardiac stimulation, highest dose causes overall vasoconstriction. Used to increase cardiac output while preserving renal function. |
|
|
Term
|
Definition
| Beta 1>beta 2 with some alpha 1 agonist activity. Beta 1 allows selective increase in force of cardiac contraction, inotropic effect>chronotropic effect |
|
|
Term
|
Definition
| Beta 2 agonist for bronchodilation |
|
|
Term
|
Definition
| Beta 2 agonist to prevent premature labor |
|
|
Term
|
Definition
| Noncompetitive alpha 1 and alpha 2 antagonist |
|
|
Term
|
Definition
| Alpha 1 antagonist, side effect of orthostatic hypertension on first dose |
|
|
Term
|
Definition
| Alpha 1A antagonist, for BPH treatment |
|
|
Term
|
Definition
| Competitive alpha 2 antagonist, produces CNS effects, also used as an aphrodisiac |
|
|
Term
|
Definition
| Beta 1 and beta 2 antagonist |
|
|
Term
|
Definition
| Beta 1 antagonist, provide exercise tolerance, better recovery from hypoglycemic episodes |
|
|
Term
|
Definition
| Beta blocker with intrinsic sympathomimetic activity, blocks increase in heat rate and cardiac output |
|
|
Term
|
Definition
| Beta and alpha antagonist with anti-oxidant and antiproliferative activity. Reduces morbidity and mortality in patients with moderate heart failure |
|
|
Term
|
Definition
| Beta and alpha antagonist used for hypertension in pregnancy |
|
|
Term
|
Definition
| prevents vesicular storage of catecholamines to lower blood pressure, but causes depression as a side effect |
|
|
